# US 6,727,274 B2 · Arylsulphonyl substituted-tetrahydro- and hexahydro-carbazoles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,274 B2
- Document ID: US6727274B2
- Status: Granted
- Kind: B2
- Application number: 10/268,627
- Filed: 2002-10-08
- Published: 2003-05-29
- Granted: 2004-04-27
- Earliest claimed: 2001-10-09
- Assignees: Pharmacia & Upjohn Company
- Inventors: Jian-Min Fu
- Web page: https://patentgrep.com/patent/US6727274B2

## CPC

- C07D 209/88: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compounds of formula I for use in treating conditions in which 5-HT6 receptors are involved such as in anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy, and other CNS disorders.

## Claims

### Claim 1

A compound of formula I
wherein
- - - [b] is a single or double bond;
Each X, Y, and Z is independently selected from H, —OH, —O-alkyl, and —O-substituted alkyl;
R1 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;
R2 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;
R3 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl;
Each R4, R5, R6, and R7 is independently selected from H, halogen, aryl, —CN, —NO2, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and —S(O)naryl, provided that one of R4, R5, R6, and R7 is —S(O)naryl, and that at least one of R4, R5, R6, and R7 is H;
n is 0, 1, or 2; and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

A compound of claim 1 having the Formula Ib
wherein
Each X, Y, and Z is independently selected from H, —OH, —O-alkyl, and —O-substituted alkyl;
R1 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;
R2 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;
R3 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl;
Each R4, R5, R6, and R7 is independently selected from H, halogen, aryl, —CN, —NO2, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and —S(O)naryl, provided that one of R4, R5, R6, and R7 is —S(O)naryl, and that at least one of R4, R5, R6, and R7 is H;
n is 0, 1, or 2; and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 2)

The compound of claim 2, wherein one of R1 and R2 is H, and the other is H, alkyl, or substituted alkyl.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R5 is aryl S(O)n—, and wherein R4, R6, and R7 are H.

### Claim 5 (depends on 4)

The compound of claim 4, wherein n is 2.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R3 is H or alkyl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein the compound is
(rac)-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1H-carbazol-3-amine;
(3S)-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1H-carbazol-3-amine;
(3R)-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1H-carbazol-3-amine;
(3S)-9-methyl-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1H-carbazol-3-amine;
(3R)-9-methyl-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1H-carbazol-3-amine;
(3R)-N,9-dimethyl-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine;
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The compound of claim 7, wherein the stereochemistry at the C-3 position is R.

### Claim 9 (depends on 8)

The compound of claim 8, wherein the compound is
(3R)-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1H-carbazol-3-amine;
(3R)-9-methyl-6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1H-carbazol-3-amine;
(3R)-N,9-dimethyl-6-(phenylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine;
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 2)

A pharmaceutical composition comprising a compound according to claim 2.

### Claim 11 (depends on 2)

A method for treating a disease or condition, in a mammal in need thereof, selected from the group consisting of anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, or epilepsy comprising administering to the mammal a therapeutically effective amount of compound according to claim 2.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said compound is administered rectally, topically, orally, sublingually, or parenterally.

### Claim 13 (depends on 11)

The method according to claim 11, wherein said compound is administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.

### Claim 14 (depends on 11)

The method according to claim 11, wherein said compound is administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.

### Claim 15 (depends on 2)

The compound of claim 2, wherein the compound includes at least one atom selected from Carbon-11, Nitrogen-13, Oxygen-15, and Fluorine-18.

### Claim 16 (depends on 1)

A compound of claim 1 having the Formula Ia
wherein
Each X, Y, and Z is independently selected from H, —OH, —O-alkyl, and —O-substituted alkyl;
R1 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;
R2 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and aryl;
R3 is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl;
Each R4, R5, R6, and R7 is independently selected from H, halogen, aryl, —CN, —NO2, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, and —S(O)naryl, provided that one of R4, R5, R6, and R7 is —S(O)naryl, and that at least one of R4, R5, R6, and R7 is H;
n is 0, 1, or 2; and pharmaceutically acceptable salts thereof.

### Claim 17 (depends on 16)

The compound of claim 16, wherein one of R1 and R2 is H, and the other is H, alkyl, or substituted alkyl.

### Claim 18 (depends on 17)

The compound of claim 17, wherein R5 is arylS(O)n—, and wherein R4, R6, and R7 are H.

### Claim 19 (depends on 18)

The compound of claim 18, wherein n is 2.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R3 is H or alkyl.

### Claim 21 (depends on 20)

The compound of claim 20, wherein the compound is selected from
(3R)-9-methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;
(3S)-9-methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;
(3R)-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;
(3S)-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;
(rac)-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol;
(3S)-N,9-dimethyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;
(3R)-N,9-dimethyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;
and pharmaceutically acceptable salts thereof.

### Claim 22 (depends on 20)

The compound of claim 20, wherein the stereochemistry at the C-3 position is R.

### Claim 23 (depends on 22)

The compound of claim 22, wherein the compound is
(3R)-9-methyl-6-(phenylsulfonyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-3-amine;
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 16)

A pharmaceutical composition comprising a compound according to claim 16.

### Claim 25 (depends on 16)

A method for treating a disease or condition, in a mammal in need thereof, selected from the group consisting of anxiety, depression, schizophrenia, Alzheimer's disease, stress-related disease, panic, a phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, or epilepsy comprising administering to the mammal a therapeutically effective amount of compound according to claim 16.

### Claim 26 (depends on 25)

The method according to claim 25, wherein said compound is administered rectally, topically, orally, sublingually, or parenterally.

### Claim 27 (depends on 25)

The method according to claim 25, wherein said compound is administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.

### Claim 28 (depends on 25)

The method according to claim 25, wherein said compound is administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.

### Claim 29 (depends on 16)

The compound of claim 16, wherein the compound includes at least one atom selected from Carbon-11, Nitrogen-13, Oxygen-15, and Fluorine-18.
